Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dialysis drug showdown: which vitamin d works best?

NCT ID NCT07640347

Disease control Sponsor: Chittagong Medical College Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two vitamin D medications—doxercalciferol (given through a vein) and calcitriol (taken by mouth)—to see which is better at lowering parathyroid hormone levels in kidney dialysis patients. About 98 adults on dialysis with high parathyroid hormone will take part. The goal is to find a more effective way to manage this common complication and reduce bone and heart risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 98 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult patients aged 18 years or older. 2. Diagnosed with secondary hyperparathyroidism (SHPT) with elevated serum PTH levels (\>300 pg/mL). 3. Undergoing maintenance hemodialysis for at least 3 months. 4. Patients on calcitriol therapy within wash out period 40 hrs. Exclusion Criteria: 1. Patients with known case of primary hyperparathyroidism or parathyroidectomy. 2. Serum calcium\>10mg/dL or phosphate\>5.5mg/dL at baseline. 3. Active liver disease or significant hepatic dysfunction, Alcoholism. 4. History of hypersensitivity to vitamin D analogs. 5. Pregnant or breastfeeding women. 6. Concurrent use of medications (e.g. bisphosphonates). 7. Patients with active malignancy.(e.g.Multiple myeloma,Bronchogenic carcinoma)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lowering parathyroid hormone level in patients on hemodioalysis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

secondary hyperparathyroidism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lowering parathyroid hormone level in patients on hemodioalysis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.